Actively Recruiting
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
Led by Virginia Commonwealth University · Updated on 2026-03-13
53
Participants Needed
1
Research Sites
329 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To determine feasibility of recruitment and tolerability of treatment with sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure.
CONDITIONS
Official Title
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 39 years or younger at the time of cancer diagnosis
- Clinical records sufficient to confirm diagnosis and treatment
- Previous treatment with anthracycline chemotherapy
- Global longitudinal strain less than 18% and/or left ventricular ejection fraction below normal but 40% or higher on echocardiogram or cardiac MRI
- No symptoms of heart failure (no undue fatigue, palpitations, or shortness of breath during normal activity)
You will not qualify if you...
- Age under 18 years
- Unable to provide consent or have a legally authorized representative
- Active psychiatric illness that may affect study compliance
- Limited English or Spanish proficiency that may affect understanding or safety
- Participation in another intervention study within 30 days or recent investigational drug use
- More than mild mitral or aortic valve disease before cancer therapy
- Severe kidney disease (GFR below 30 mL/min/1.73m2)
- Chronic high potassium levels (above 5 mmol/L)
- Recent COVID-19 infection or exposure
- More than moderate tricuspid or pulmonary valve disease before cancer therapy
- Significant congenital heart disease excluding minor defects
- More than moderate pericardial effusion
- Diagnosed constrictive cardiomyopathy before cancer therapy
- Family history of genetic cardiomyopathy
- Evidence of infiltrative cardiomyopathy
- Symptomatic heart disease by NYHA classification
- Allergy to valsartan or sacubitril
- Unable to complete cardiac MRI or 6-minute walk test
- Unable to measure blood pressure and heart rate at home
- Pregnant or lactating
- Severe allergic reactions to gadolinium contrast (imaging without contrast may be done)
- Use of ACE inhibitors, ARBs, aliskiren, NSAIDs, or lithium that cannot be stopped for the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Virginia Commonwealth University
Richmond, Virginia, United States, 23298
Actively Recruiting
Research Team
M
Massey CTO CPC Team
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here